Description: Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceutical, and health products in Taiwan. It operates through New Drug Research and Development, and Agricultural Products Cultivation segments. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers; and OB318, an anti-cancer drug that is in Phase I clinical trials. It is also developing FB704A that has completed Phase I clinical trial for the treatment of rheumatoid arthritis; FB825, which is in Phase IIa clinical trial for treating atopic dermatitis, allergic diseases, and asthma; and FB918, an antibody targeting the interleukin 33 that is in pre-clinical stage for the treatment of asthma. In addition, the company engages in the management of agriculture cultivation and trading business; and sale of agricultural products. Oneness Biotech Co., Ltd. was incorporated in 2008 and is headquartered in Taipei, Taiwan.
Home Page: www.onenessbio.com
No.236, Xinyi Road
Taipei,
106
Taiwan
Phone:
886 2 2703 1098
Officers
| Name | Title |
|---|---|
| Ms. Chih-Hui Cheng | GM & Supervisor of Corp. Governance |
| Ms. Debbie Fang | Mang. of Fin. Department |
| Ms. Wen-Tzu Hsiao | Acting Spokesperson & Sr. Mang. of Fin. Department |
| Shyi-Gen Chen M.D., M.P.H. | VP & Head of Medical Affairs |
| Dr. Jui-Ching Chen Ph.D. | Director of New Drug Devel. Department |
| Mr. Kung-Ming Lu | Director of Operation Center |
| Mr. Nien-Yi Chen | Deputy Gen. Mang. of Antibody New Drug Division; |
Exchange: TWO
Country: TW : Taiwan
Currency: New Taiwan Dollar (NT$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 83.4532 |
| Price-to-Book MRQ: | 6.5357 |
| Price-to-Sales TTM: | 88.1683 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |